← Back to Search

Multi-level Multi-Component Intervention (MLI) for COVID-19

N/A
Waitlist Available
Led By Maria Fernandez, PhD
Research Sponsored by The University of Texas Health Science Center, Houston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through study completion (26 months)
Awards & highlights

Study Summary

In collaboration with community partners, this study will identify disparities and dynamics of COVID-19 testing and infections in three Texas regions; and implement a multilevel intervention that increases access to testing and referrals to follow-up care among vulnerable populations. Using a three-arm group-randomized controlled trial, this study will assess the impact of multi-level interventions influencing motivation and access to testing. The outcomes of this study are measured at the population level and no individual data will be gathered. Analyses of de-identified PHI data from local and regional health departments on COVID testing and infection rates will be used to assess intervention outcomes.

Eligible Conditions
  • COVID-19
  • Coronavirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through study completion (26 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through study completion (26 months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Testing Uptake
Secondary outcome measures
Disparities in Testing

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Multi-level Multi-Component Intervention (MLI)Experimental Treatment1 Intervention
Individuals receive COVID-19 CHW-delivered education and navigation, 2-1-1 helpline referrals, and social marketing messaging.
Group II: Community Just-in-Time-Adaptive Intervention (JITAI)Experimental Treatment1 Intervention
Individuals receive MLI intervention components that are informed by real-time data and community stakeholder feedback.
Group III: Comparison ConditionActive Control1 Intervention
Individuals receive standard exposure to ongoing city and county COVID-19 communication and testing.

Find a Location

Who is running the clinical trial?

National Center for Advancing Translational Sciences (NCATS)NIH
320 Previous Clinical Trials
400,450 Total Patients Enrolled
20 Trials studying COVID-19
266,167 Patients Enrolled for COVID-19
The University of Texas Health Science Center, HoustonLead Sponsor
903 Previous Clinical Trials
319,697 Total Patients Enrolled
6 Trials studying COVID-19
9,229 Patients Enrolled for COVID-19
Maria Fernandez, PhDPrincipal InvestigatorThe University of Texas Health Science Center, Houston

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this study currently seeking participants?

"This trial, which was initially listed on June 7th 2021 is no longer recruiting patients. The last update to the study's information occurred November 3rd 2022 according to clinicaltrials.gov. Despite this particular research project not being open for enrolment, there are still over 1000 other studies that require new participants at this time."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Using a Community-level Just-in-Time Adaptive Intervention to Address COVID-19 Testing Disparities
Maria E Fernandez 2021. "Using a Community-level Just-in-Time Adaptive Intervention to Address COVID-19 Testing Disparities". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05606003.
~334 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top